What is Bioventus Inc.'s earnings per share (EPS)?

Bioventus Inc. (BVS) reported diluted earnings per share of $0.33 for fiscal year 2025. This represents a 158.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bioventus Inc. Financials

BVS

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Bioventus Inc. (BVS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 45/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Bioventus Inc. has an operating margin of 9.5%, meaning the company retains $10 of operating profit per $100 of revenue. This results in a moderate score of 43/100, indicating healthy but not exceptional operating efficiency. This is up from -2.6% the prior year.

Growth

Bioventus Inc.'s revenue declined 0.9% year-over-year, from $573.3M to $568.1M. This contraction results in a growth score of 32/100.

Leverage

Bioventus Inc. carries a low D/E ratio of 1.52, meaning only $1.52 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 71/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Bioventus Inc.'s current ratio of 1.70 indicates adequate short-term liquidity, earning a score of 30/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Bioventus Inc. has a free cash flow margin of 12.7%, earning a moderate score of 57/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Bioventus Inc.'s ROE of 12.3% shows moderate profitability relative to equity, earning a score of 39/100. This is up from -24.4% the prior year.

Altman Z-Score Distress

1.42

Bioventus Inc. scores 1.42, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($616.4M) relative to total liabilities ($455.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Strong

8/9

Bioventus Inc. passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

3.28x

For every $1 of reported earnings, Bioventus Inc. generates $3.28 in operating cash flow ($74.7M OCF vs $22.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$568.1M

YoY-0.9%

5Y CAGR+12.1%

Bioventus Inc. generated $568.1M in revenue in fiscal year 2025. This represents a decrease of 0.9% from the prior year.

EBITDA

$101.0M

YoY+193.9%

5Y CAGR+15.2%

Bioventus Inc.'s EBITDA was $101.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 193.9% from the prior year.

Net Income

$22.7M

YoY+162.9%

5Y CAGR+6.7%

Bioventus Inc. reported $22.7M in net income in fiscal year 2025. This represents an increase of 162.9% from the prior year.

EPS (Diluted)

$0.33

YoY+158.9%

Bioventus Inc. earned $0.33 per diluted share (EPS) in fiscal year 2025. This represents an increase of 158.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$72.1M

YoY+90.8%

5Y CAGR+5.5%

Bioventus Inc. generated $72.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 90.8% from the prior year.

Cash & Debt

$51.2M

YoY+23.2%

5Y CAGR-10.0%

Bioventus Inc. held $51.2M in cash against $279.0M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

68.3%

YoY+0.6pp

5Y CAGR-4.4pp

Bioventus Inc.'s gross margin was 68.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.6 percentage points from the prior year.

Operating Margin

9.5%

YoY+12.2pp

5Y CAGR+2.9pp

Bioventus Inc.'s operating margin was 9.5% in fiscal year 2025, reflecting core business profitability. This is up 12.2 percentage points from the prior year.

Net Margin

4.0%

YoY+10.3pp

5Y CAGR-1.1pp

Bioventus Inc.'s net profit margin was 4.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 10.3 percentage points from the prior year.

Return on Equity

12.3%

YoY+36.8pp

5Y CAGR+1.0pp

Bioventus Inc.'s ROE was 12.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 36.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$12.1M

YoY-13.2%

5Y CAGR+1.6%

Bioventus Inc. invested $12.1M in research and development in fiscal year 2025. This represents a decrease of 13.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$2.6M

YoY+154.7%

5Y CAGR-31.2%

Bioventus Inc. invested $2.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 154.7% from the prior year.

BVS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$568.1M-0.9%	$573.3M+11.9%	$512.3M0.0%	$512.1M+18.8%	$430.9M+34.2%	$321.2M
Cost of Revenue	$179.9M-2.8%	$185.1M+0.5%	$184.2M+1.7%	$181.0M+41.2%	$128.2M+46.3%	$87.6M
Gross Profit	$388.2M0.0%	$388.2M+18.3%	$328.2M-0.9%	$331.1M+9.4%	$302.7M+29.6%	$233.5M
R&D Expenses	$12.1M-13.2%	$14.0M+3.8%	$13.4M-43.6%	$23.9M+25.3%	$19.0M+70.0%	$11.2M
SG&A Expenses	$314.0M-8.7%	$343.8M+13.1%	$303.9M-8.5%	$332.1M+30.6%	$254.3M+31.7%	$193.1M
Operating Income	$54.0M+455.2%	-$15.2M+81.4%	-$81.7M+51.1%	-$167.2M-1486.6%	$12.1M-43.2%	$21.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$1.6M+70.4%	-$5.3M-6327.1%	$85K+100.2%	-$44.4M-2157.1%	-$2.0M-264.9%	$1.2M
Net Income	$22.7M+162.9%	-$36.1M+76.9%	-$156.2M+1.6%	-$158.7M-919.1%	$19.4M+18.1%	$16.4M
EPS (Diluted)	$0.33+158.9%	$-0.56+77.5%	$-2.49+3.9%	$-2.59-1626.7%	$-0.15	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$157.9M+13.9%	$138.7M-6.1%	$147.7M+19.2%	$123.9M-19.4%	$153.6M+10.6%	$139.0M-8.1%	$151.2M+16.8%	$129.5M
Cost of Revenue	$49.1M+10.6%	$44.4M-2.5%	$45.6M+11.6%	$40.8M-19.9%	$51.0M+12.3%	$45.4M-4.6%	$47.6M+15.8%	$41.1M
Gross Profit	$108.8M+15.4%	$94.2M-7.7%	$102.1M+22.9%	$83.1M-19.1%	$102.7M+9.7%	$93.6M-9.7%	$103.6M+17.3%	$88.4M
R&D Expenses	$3.0M+2.9%	$2.9M-7.8%	$3.2M+5.3%	$3.0M-7.9%	$3.3M-14.9%	$3.8M-8.7%	$4.2M+60.3%	$2.6M
SG&A Expenses	$82.8M+5.2%	$78.7M-0.6%	$79.1M+7.6%	$73.5M-15.4%	$86.9M+6.6%	$81.5M-15.7%	$96.7M+22.7%	$78.8M
Operating Income	$19.5M+73.2%	$11.3M-38.7%	$18.4M+277.2%	$4.9M-36.8%	$7.7M+111.2%	$3.6M+111.6%	-$31.5M-738.7%	$4.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$3.2M-578.2%	$664K-36.2%	$1.0M+1195.8%	-$95K-117.3%	$550K-6.6%	$589K+108.0%	-$7.3M-909.2%	$907K
Net Income	$14.8M+367.7%	$3.2M-57.7%	$7.5M+382.9%	-$2.6M-579.6%	-$388K+92.5%	-$5.2M+79.9%	-$25.7M-425.2%	-$4.9M
EPS (Diluted)	N/A	$0.05-54.5%	$0.11+375.0%	$-0.04	N/A	$-0.08+80.0%	$-0.40-400.0%	$-0.08

BVS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$683.6M-6.1%	$728.0M-10.2%	$810.9M-40.9%	$1.4B+12.0%	$1.2B+147.9%	$494.5M
Current Assets	$272.8M-1.0%	$275.6M+2.8%	$268.0M-1.7%	$272.6M+3.6%	$263.1M+24.2%	$211.8M
Cash & Equivalents	$51.2M+23.2%	$41.6M+12.5%	$37.0M+22.5%	$30.2M-31.3%	$43.9M-49.4%	$86.8M
Inventory	$82.2M-11.1%	$92.5M+1.3%	$91.3M+7.7%	$84.8M+37.4%	$61.7M+111.8%	$29.1M
Accounts Receivable	$128.3M+0.7%	$127.4M+3.7%	$122.8M-9.9%	$136.3M+9.1%	$125.0M+41.5%	$88.3M
Goodwill	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M-94.9%	$147.6M+196.4%	$49.8M
Total Liabilities	$455.1M-16.1%	$542.4M-8.0%	$589.8M-38.6%	$960.4M+55.4%	$618.2M+76.5%	$350.3M
Current Liabilities	$160.4M-23.8%	$210.4M+19.9%	$175.5M-42.3%	$304.0M+68.1%	$180.9M+47.5%	$122.6M
Long-Term Debt	$279.0M-9.5%	$308.3M-16.0%	$367.0M-4.7%	$385.0M+13.4%	$339.6M+95.9%	$173.4M
Total Equity	$184.1M+24.4%	$147.9M-14.8%	$173.6M-46.6%	$325.2M-29.1%	$458.9M+218.3%	$144.2M
Retained Earnings	-$334.9M+6.4%	-$357.7M-11.2%	-$321.5M-94.5%	-$165.3M-2403.9%	-$6.6M	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$683.6M-2.6%	$701.6M-0.7%	$706.8M+2.2%	$691.4M-5.0%	$728.0M-5.4%	$769.5M-2.9%	$792.2M-0.3%	$794.2M
Current Assets	$272.8M-2.9%	$280.9M+2.1%	$275.2M+10.4%	$249.4M-9.5%	$275.6M-7.7%	$298.7M-3.3%	$308.9M+16.2%	$265.9M
Cash & Equivalents	$51.2M+21.5%	$42.2M+28.1%	$32.9M+44.3%	$22.8M-45.2%	$41.6M-3.5%	$43.1M+34.6%	$32.0M+27.1%	$25.2M
Inventory	$82.2M-14.6%	$96.3M-0.2%	$96.5M+2.6%	$94.0M+1.7%	$92.5M+2.7%	$90.0M+2.8%	$87.6M-9.7%	$97.0M
Accounts Receivable	$128.3M-1.6%	$130.4M-1.5%	$132.4M+12.1%	$118.1M-7.3%	$127.4M+4.5%	$121.9M-11.2%	$137.3M+9.4%	$125.5M
Goodwill	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M
Total Liabilities	$455.1M-7.9%	$494.3M-2.2%	$505.5M-0.1%	$505.9M-6.7%	$542.4M-6.9%	$582.7M-3.4%	$603.1M+4.6%	$576.8M
Current Liabilities	$160.4M-0.8%	$161.8M-12.9%	$185.7M+6.3%	$174.8M-16.9%	$210.4M-0.5%	$211.5M-8.6%	$231.5M+33.5%	$173.3M
Long-Term Debt	$279.0M-10.4%	$311.3M+4.5%	$297.9M-3.5%	$308.6M+0.1%	$308.3M-10.6%	$345.0M+0.1%	$344.7M-3.0%	$355.4M
Total Equity	$184.1M+10.8%	$166.1M+3.0%	$161.2M+8.8%	$148.1M+0.1%	$147.9M-0.5%	$148.7M-1.5%	$150.9M-11.9%	$171.3M
Retained Earnings	-$334.9M+4.2%	-$349.7M+0.9%	-$352.8M+2.1%	-$360.3M-0.7%	-$357.7M-0.8%	-$354.9M-1.4%	-$350.1M-7.4%	-$326.1M

BVS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$74.7M+92.5%	$38.8M+152.8%	$15.3M+213.3%	-$13.5M-158.9%	$23.0M-68.0%	$71.8M
Capital Expenditures	$2.6M+154.7%	$1.0M-86.3%	$7.4M+398.1%	$1.5M-89.1%	$13.5M-18.5%	$16.6M
Free Cash Flow	$72.1M+90.8%	$37.8M+373.4%	$8.0M+153.2%	-$15.0M-258.5%	$9.5M-82.8%	$55.2M
Investing Cash Flow	-$3.2M-114.1%	$23.0M+45.3%	$15.8M+113.6%	-$116.4M+59.0%	-$283.8M-1284.2%	-$20.5M
Financing Cash Flow	-$62.1M-13.9%	-$54.6M-104.8%	-$26.7M-142.9%	$62.1M-77.3%	$273.4M+1024.5%	-$29.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$38.0M+26.1%	$30.1M+16.0%	$25.9M+234.2%	-$19.3M-200.0%	$19.3M+87.3%	$10.3M-32.0%	$15.2M+352.5%	-$6.0M
Capital Expenditures	$580K+22.6%	$473K-30.7%	$683K-17.3%	$826K+43.9%	$574K+796.9%	$64K-16.9%	$77K-73.5%	$291K
Free Cash Flow	$37.4M+26.2%	$29.6M+17.3%	$25.3M+225.3%	-$20.2M-207.5%	$18.7M+82.9%	$10.3M-32.0%	$15.1M+339.6%	-$6.3M
Investing Cash Flow	-$580K-22.6%	-$473K+65.4%	-$1.4M-65.7%	-$826K-103.4%	$24.1M+37762.5%	-$64K+16.9%	-$77K+92.3%	-$1.0M
Financing Cash Flow	-$28.4M-42.4%	-$20.0M-36.2%	-$14.7M-1648.4%	$947K+102.2%	-$42.9M-11938.4%	$362K+104.6%	-$7.8M-84.9%	-$4.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BVS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	68.3%+0.6pp	67.7%+3.7pp	64.1%-0.6pp	64.6%-5.6pp	70.3%-2.5pp	72.7%
Operating Margin	9.5%+12.2pp	-2.6%+13.3pp	-16.0%+16.7pp	-32.7%-35.5pp	2.8%-3.8pp	6.6%
Net Margin	4.0%+10.3pp	-6.3%+24.2pp	-30.5%+0.5pp	-31.0%-35.5pp	4.5%-0.6pp	5.1%
Return on Equity	12.3%+36.8pp	-24.4%+65.6pp	-90.0%-41.2pp	-48.8%-53.0pp	4.2%-7.2pp	11.4%
Return on Assets	3.3%+8.3pp	-5.0%+14.3pp	-19.3%-7.7pp	-11.6%-13.1pp	1.6%-1.7pp	3.3%
Current Ratio	1.70+0.4	1.31-0.2	1.53+0.6	0.90-0.6	1.45-0.3	1.73
Debt-to-Equity	1.52-0.6	2.08-0.0	2.11+0.9	1.18+0.4	0.74-0.5	1.20
FCF Margin	12.7%+6.1pp	6.6%+5.0pp	1.6%+4.5pp	-2.9%-5.1pp	2.2%-15.0pp	17.2%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	68.9%+0.9pp	68.0%-1.2pp	69.1%+2.1pp	67.0%+0.2pp	66.8%-0.5pp	67.3%-1.2pp	68.5%+0.3pp	68.3%
Operating Margin	12.3%+4.2pp	8.1%-4.3pp	12.4%+8.5pp	3.9%-1.1pp	5.0%+2.4pp	2.6%+23.4pp	-20.8%-24.6pp	3.8%
Net Margin	9.3%+7.1pp	2.3%-2.8pp	5.1%+7.2pp	-2.1%-1.9pp	-0.3%+3.5pp	-3.7%+13.3pp	-17.0%-13.2pp	-3.8%
Return on Equity	8.0%+6.1pp	1.9%-2.7pp	4.6%+6.4pp	-1.8%-1.5pp	-0.3%+3.2pp	-3.5%+13.5pp	-17.0%-14.2pp	-2.9%
Return on Assets	2.2%+1.7pp	0.4%-0.6pp	1.1%+1.4pp	-0.4%-0.3pp	-0.1%+0.6pp	-0.7%+2.6pp	-3.2%-2.6pp	-0.6%
Current Ratio	1.70-0.0	1.74+0.3	1.48+0.1	1.43+0.1	1.31-0.1	1.41+0.1	1.33-0.2	1.53
Debt-to-Equity	1.52-0.4	1.87+0.0	1.85-0.2	2.080.0	2.08-0.2	2.32+0.0	2.28+0.2	2.08
FCF Margin	23.7%+2.3pp	21.4%+4.3pp	17.1%+33.4pp	-16.3%-28.5pp	12.2%+4.8pp	7.4%-2.6pp	10.0%+14.8pp	-4.9%

Similar Companies

STANDARD BIOTOOLS INC LAB

$358.6M

Treace Medical Concepts, Inc. TMCI

$86.6M

Surmodics Inc SRDX

$614.5M

Orthofix Med Inc OFIX

$460.5M

Avanos Medical AVNS

$651.6M

Frequently Asked Questions

What is Bioventus Inc.'s annual revenue?

Bioventus Inc. (BVS) reported $568.1M in total revenue for fiscal year 2025. This represents a -0.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bioventus Inc.'s revenue growing?

Bioventus Inc. (BVS) revenue declined by 0.9% year-over-year, from $573.3M to $568.1M in fiscal year 2025.

Is Bioventus Inc. profitable?

Yes, Bioventus Inc. (BVS) reported a net income of $22.7M in fiscal year 2025, with a net profit margin of 4.0%.

What is Bioventus Inc.'s EBITDA?

Bioventus Inc. (BVS) had EBITDA of $101.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Bioventus Inc. have?

As of fiscal year 2025, Bioventus Inc. (BVS) had $51.2M in cash and equivalents against $279.0M in long-term debt.

What is Bioventus Inc.'s gross margin?

Bioventus Inc. (BVS) had a gross margin of 68.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Bioventus Inc.'s operating margin?

Bioventus Inc. (BVS) had an operating margin of 9.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Bioventus Inc.'s net profit margin?

Bioventus Inc. (BVS) had a net profit margin of 4.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Bioventus Inc.'s return on equity (ROE)?

Bioventus Inc. (BVS) has a return on equity of 12.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bioventus Inc.'s free cash flow?

Bioventus Inc. (BVS) generated $72.1M in free cash flow during fiscal year 2025. This represents a 90.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bioventus Inc.'s operating cash flow?

Bioventus Inc. (BVS) generated $74.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bioventus Inc.'s total assets?

Bioventus Inc. (BVS) had $683.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Bioventus Inc.'s capital expenditures?

Bioventus Inc. (BVS) invested $2.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Bioventus Inc. spend on research and development?

Bioventus Inc. (BVS) invested $12.1M in research and development during fiscal year 2025.

What is Bioventus Inc.'s current ratio?

Bioventus Inc. (BVS) had a current ratio of 1.70 as of fiscal year 2025, which is generally considered healthy.

What is Bioventus Inc.'s debt-to-equity ratio?

Bioventus Inc. (BVS) had a debt-to-equity ratio of 1.52 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bioventus Inc.'s return on assets (ROA)?

Bioventus Inc. (BVS) had a return on assets of 3.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bioventus Inc.'s Altman Z-Score?

Bioventus Inc. (BVS) has an Altman Z-Score of 1.42, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Bioventus Inc.'s Piotroski F-Score?

Bioventus Inc. (BVS) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bioventus Inc.'s earnings high quality?

Bioventus Inc. (BVS) has an earnings quality ratio of 3.28x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Bioventus Inc.?

Bioventus Inc. (BVS) scores 45 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.